Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Promising novel agents for relapsed/refractory multiple myeloma

Enrique Ocio • 14 May 2022
COMy 2022
Multiple Myeloma Antibodies Belantamab mafodotin CC-92480 Iberdomide Lenalidomide Pomalidomide Selinexor Thalidomide

Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, briefly discusses novel therapeutic agents for the treatment of relapsed/refractory (R/R) multiple myeloma, including cereblon E3 ligase modulators (CELMoDs) such as iberdomide and CC-92480, selinexor, belantamab mafodotin, and other novel targets. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals